Autotransfusion Devices: Global Strategic Business Report

Global Autotransfusion Devices Market to Reach $2.1 Billion by 2030

The global market for Autotransfusion Devices estimated at US$1.4 Billion in the year 2022, is projected to reach a revised size of US$2.1 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2022-2030. On Pump Transfusion Devices, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$959.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Off Pump transfusion Devices segment is readjusted to a revised 5.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $414.5 Million, While China is Forecast to Grow at 5.2% CAGR

The Autotransfusion Devices market in the U.S. is estimated at US$414.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$371.2 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 4.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Select Competitors (Total 38 Featured) -

• Advancis Surgical
• Atrium Medical Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• LivaNova PLC
• Medtronic PLC
• Stryker Corporation
• Terumo Corporation

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year